PRINCETON, N.J., Oct. 17 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) today announced that effective October 22, 2007, Ursula B.
Bartels is appointed Senior Vice President of the company. Following a
brief transition period, Ms. Bartels will assume full responsibilities of
General Counsel and Secretary of Medarex from W. Bradford Middlekauff. Mr.
Middlekauff will become Senior Vice President, Strategic Planning of
Medarex. Ms. Bartels will oversee Medarex's legal department and be
responsible for the company's global legal strategy.
Ms. Bartels brings to Medarex more than 20 years of industry
experience. She was most recently Vice President, General Counsel and
Secretary of Chiron Corporation until April 2006, when it was acquired by
Novartis. Prior to joining Chiron, Ms. Bartels served as Senior Vice
President, General Counsel and Secretary of Boehringer Ingelheim
Corporation, where she was responsible for all legal, and compliance
functions for the US businesses. Before that, she spent 11 years at
SmithKline Beecham Corporation, serving in various capacities in the legal
department, culminating in the position of Vice President and Associate
General Counsel, Legal Operations North America. Ms. Bartels received her
J.D. from the University of Virginia, and did her undergraduate work at
Bryn Mawr College.
"Ursula brings enormous experience to Medarex," said Howard H. Pien,
President and CEO of Medarex. "With her deep knowledge of the
pharmaceutical industry and broad range of experiences in corporate
governance, regulatory compliance, and global intellectual property
strategy, I have complete confidence that Ursula will be an invaluable
addition to the Medarex management team as we continue to grow and
strengthen our position in the field of antibody therapeutics."
Mr. Pien also said, "I'd like to thank Brad Middlekauff for his
contribution to Medarex over the last seven years, during which he has
played a key role."
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 30 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase III clinical trials. Medarex is committed to building
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit
its website at http://www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.
SOURCE Medarex, Inc.
 back to top
Related links:
http://www.medarex.com
http://www.prnewswire.com/comp/108265.html /
CONTACT:
Laura S. Choi, Investor Relations,
+1-609-430-2880, ext. 2216, or Jean Mantuano, Corporate
Communications (media), +1-609-430-2880, ext. 2221, both of
Medarex, Inc.
|
